Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.

Abstract: The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFRxCD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1) are also provided. The EGFRxCD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T-cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tumoral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models.

Abstract: The present disclosure provides methods of administering bispecific antibodies and antigen-binding fragments thereof that specifically bind to human Programmed cell-death-1 (PD-1) and Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) to a subject in need thereof, for example, a subject with cancer.

Abstract: The present disclosure relates to the use of an anti-BTLA antagonist (including antibodies and antigen binding fragments) in the treatment of various tumors, either as a mono therapy or a combination therapy with other immune checkpoint inhibitor therapy such as anti-PD-1 or anti-PD-L1, and methods of selecting subjects in need of treatment. Preferably, various solid tumors are treated.

Abstract: Provided are a combination of an anti-PD-1 antibody or an antigen binding fragment of the anti-PD-1 antibody and a cytotoxic anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer. Specifically, Provided are a combination of an anti-PD-1 antibody or an antigen-binding fragment of the anti-PD-1 antibody, an anti-folate metabolism anticancer drug, and a platinum anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer that has failed EGFR-TKI treatment.

Abstract: Provided are bispecific proteins that comprise a binding domain binding cell surface protein and a vascular endothelial growth factor (VEGF) inhibiting domain. Provided also is an antibody-drug conjugate that comprises a therapeutic agent and an antibody or an antigen-binding fragment binding PD-L1 and/or a VEGF inhibiting domain, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.

Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity.

Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

Abstract: The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.

Abstract: Provided herein are IL10R binding molecules that bind to IL10Ra and IL10Rb and comprise an IL10Rb sdAb and an IL10Rb VHH antibody.

Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.

Abstract: Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.

Abstract: The disclosure relates to an anti-CD44 single-chain antibody and use thereof in preparing a drug for treating a tumor. The amino acid sequence of the anti-CD44 single-chain antibody includes a sequence shown in SEQ ID NO. 1. T lymphocytes expressing the anti-CD44 single-chain antibody provided in the present disclosure can specifically kill CD44-positive tumor cells and have high specificity as well as strong killing ability.

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Abstract: The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.

Abstract: An antibody or an antigen-binding fragment thereof that binds to human CD38. The antibody or the antigen-binding fragment thereof can effectively bind to human CD38 and is applied to preparing a drug for treating diseases having strong CD38 expression (such as multiple myeloma), thereby having good prospects in clinical application.

Abstract: Provided herein are antibody molecules that bind specifically to CD122 and antigen-binding portions thereof and related compositions, nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

Abstract: The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with a antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the transduced T cells of the invention and/or nucleic acid molecules, vectors encoding the antigen binding receptors of the present invention and tumor targeting antibodies comprising a mutated Fc domain.

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Abstract: The invention provides a multispecific molecule capable of simultaneous binding to a Mucosal Associated Invariant T (MAIT) cell and a tumor cell, which multispecific molecule comprises at least one domain that specifically binds a V?7.2 T cell receptor (TCR) and at least one domain that specifically binds a tumor associated antigen (TAA).

Abstract: Disclosed is a binding protein having at least two protein functional regions, the binding protein comprising a protein functional region A and a protein functional region B; the protein functional region A and the protein functional region B target different antigens or epitopes, the protein functional region A is a Fab or a scFv structure, the protein functional region B is a VH structure, and there are one or more of each of the protein functional region A and the protein functional region B. A multi-specific binding protein has a smaller molecular weight, fewer polypeptide chains, and a simpler structure. By means of different structure types, relative positions, binding valence and other parameters, the functional activities for different targets can be adjusted, and then different combinations of activities can be designed so as to meet the needs of different dose combinations of clinical combinations.

Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new placement for a non-canonical disulfide bond and as such the generation of an asymmetric cysteine interface between two Fabs present in the same molecule which will further enable the production of multispecifics.

Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.

Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.

Abstract: The invention provides anti-Notch2 antibodies and conjugates and methods of using the same.

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Abstract: The present invention relates to an efficient process for the preparation of nanocelluloses using mixtures of ammonium formate and at least one acid as reactant and solvent as well as to novel modified nanocelluloses and their applications.

Abstract: Described herein is a naturally produced hydrogel chitosan layer made from shrimp shells for a biofilter system and a method of producing the hydrogel chitosan layer comprising extracting the chitosan from the shrimp shells.

Abstract: An object of the present disclosure is to provide a polymer which is recyclable and capable of performing as equally well as a new product. Another object of the present disclosure is to provide a rubber composition containing said polymer, a method for manufacturing said rubber composition, and a rubber product containing said rubber composition. To achieve the objects, the present disclosure provides a complex polymer, comprising: a polymer main chain containing a conjugated diene unit and/or an olefin unit; and a functional group bonded to the polymer main chain, wherein: the functional group contains nitrogen atom and/or phosphorus atom therein and is complexed with a metal ion of an element of group 7-10 in the Periodic Table; and the bond dissociation energy for dissociation of the metal ion and the functional group is 200 kJ/mol or more.

Abstract: The present disclosure provides a photopolymerizable composition. The photopolymerizable composition includes a) 40-60 parts by weight of a monofunctional (meth)acrylate monomer, per 100 parts of the total photopolymerizable composition; b) a photoinitiator; and c) a polymerization reaction product of components. A cured homopolymer of the monofunctional (meth)acrylate monomer has a glass transition temperature of 125 degrees Celsius or greater. The polymerization reaction product of components includes i) a diisocyanate; ii) a hydroxy functional methacrylate; iii) a polycarbonate diol; and iv) a catalyst. The polymerization reaction product includes a polyurethane methacrylate polymer.

Abstract: Embodiments of the present application are directed to procatalysts, and catalyst systems including procatalysts, including a metal-ligand complex having the structure of formula (I): [Formula I]

Abstract: A process for the preparation of an ultra-high molecular weight ethylene homopolymer having a MFR21 of 0.01 g/10 min or less, said process comprising: (I) prepolymerising at least ethylene at a temperature of 0 to 90° C. in the presence of a heterogeneous Ziegler Natta catalyst to prepare an ethylene prepolymer having an Mw of 40,000 to 600,000 g/mol; and thereafter in the presence of the prepolymer and said catalyst; (II) polymerising ethylene at a temperature of 55° C. or less, such as 20 to 55° C., to prepare said UHMW ethylene homopolymer; wherein the UHMW ethylene homopolymer comprises up to 8 wt.% of said prepolymer.

Abstract: The present invention relates to a borate compound represented by the following formula (1): wherein each symbol is as defined in [DESCRIPTION], and use thereof as a cocatalyst for the polymerization of olefin and diene.

Abstract: This invention relates to a supported catalyst system comprising: (i) at least one first catalyst component comprising a group 4 metallocycle containing metallocene complex; (ii) at least one second catalyst component comprising a 2,6-bis(imino)pyridyl iron complex; (iii) activator; and (iv) support. The catalyst system may be used for preparing polyolefins, such a bimodal polyethylene, typically in a gas phase polymerization.

Abstract: A method of determining multimodal polyethylene quality comprising the steps of (a) providing a multimodal polyethylene resin sample; (b) determining, in any sequence, the following: that the multimodal polyethylene resin sample has a melt index within 30% of a target melt index; that the multimodal polyethylene resin sample has a density within 2.5% of a target density; that the multimodal polyethylene resin sample has a dynamic viscosity deviation (% MVD) from a target dynamic viscosity of less than about 100%; that the multimodal polyethylene resin sample has a weight average molecular weight (Mw) deviation (% MwD) from a target Mw of less than about 20%; and that the multimodal polyethylene resin sample has a gel permeation chromatography (GPC) curve profile deviation (% GPCD) from a target GPC curve profile of less than about 15%; and (c) responsive to step (b), designating the multimodal polyethylene resin sample as a high quality resin.

Abstract: Embossing resins, methods of manufacturing such resins, and electrokinetic display system, which includes display cells containing such resins. The resins include a fluoropolymer in weight percentage 5%-60%, a difunctional diluent in weight percentage 0-30%, a monofunctional diluent in weight percentage 0-40%, a urethane diacrylate or functionalized nanoscale material, e.g., a functionalized urethane material, in weight percentage 5-50%, a photoinitiator in weight percentage 0.5-5%, and a surfactant in weight percentage less than 0.5%. The difunctional diluent may be Hexanediol Diacrylate, and the monofunctional diluent may be a monofunctional hydrocarbon. The resins are made by identifying a target index of refraction for a cured state thereof, and combining together, by weight percentage, the constituent components to produce the liquid state version of the embossing resin having a desired composite index of refraction.

Abstract: Provided is a method for producing an aqueous dispersion of a fluorine-containing elastomer, comprising polymerizing a fluorine-containing monomer in the presence of a polymer (1) containing a polymerization unit (1) based on a monomer (1) represented by general formula (1) and an aqueous medium, CF2?CF—R—CZ1Z2—COOM??(1) wherein R is a linking group, Z1 and Z2 are each independently F or CF3, and M is H, a metal atom, NR74, imidazolium optionally having a substituent, pyridinium optionally having a substituent, or phosphonium optionally having a substituent, wherein R7 is H or an organic group.

Abstract: A method enables evaluation of the purity of an active pharmaceutical ingredient contained in a complex, and a method of producing a complex in which the purity of the active pharmaceutical ingredient is not less than 95.0%. The purity evaluation method includes: a reaction step of reacting a complex with a nitrogen-containing nucleophile such as hydroxylamine in the presence of a protonic acid in a polar solvent; and an evaluation step of evaluating the purity of the reaction mixture obtained by the reaction step, by high-performance liquid chromatography. The method of producing a complex includes a reaction step of reacting an anthracycline drug with an N-(2-hydroxypropyl)methacrylamide polymer in the presence of a protonic acid in a polar solvent at not more than 10° C., to obtain the complex.

Abstract: An aqueous formulation for use in slick water fracturing, water treatment, enhanced oil recovery, drilling, erosion control, dust abatement or mining flotation operations includes (i) one or more than one polymer (AA) which is a water-soluble polymer; (ii) water; (iii) one or more than one quaternary ammonium compound; and (iv) one or more than one scale inhibitor.

Abstract: Provided is a cycloolefin resin cured product having oxygen barrier properties prepared through bulk polymerization of a polymerizable composition comprising a cycloolefin monomer and a metathesis polymerization catalyst, wherein the cycloolefin monomer includes a norbornene-based monomer (a), the polymerizable composition comprises an antioxidant in an amount of 0.3% by mass or less, and the cycloolefin resin cured product has an oxygen permeability at 23° C. of less than 50 mL/m2·day·atm (100 ?m).

Abstract: Provided is a polyethylene yarn having improved post-processability, and more particularly, a polyethylene yarn which maintains excellent mechanical properties even in a harsh environment such as a high temperature to have improved post-processability such as dyeing or coating is provided.

Abstract: The polyethylene powder satisfies (requirements 1 and 2). (Requirement 1): an intrinsic viscosity (IV) is 1.5 dL/g or more and 34.0 dL/g or less, and (requirement 2): a ratio ?0/?1 of an elastic limit strain ?0 at a swelling time t (h) of 0 hours to an elastic limit strain ?1 at a swelling time t (h) of 1 hour is 0.80 or more and 0.95 or less, wherein the ratio is obtained from a strain dependence test .

Abstract: An object of the present invention is to provide a cured product which is suitable as a material for a layer of low refractive index in a multilayer diffractive optical element, can exhibit a desired chromatic aberration reducing effect over a near-infrared wavelength region to a shortwave infrared wavelength region in a case of being used in the multilayer diffractive optical element, and can exhibit high transmittance in this wavelength range; a curable resin composition suitable for obtaining this cured product; and a diffractive optical element and a multilayer diffractive optical element including this cured product. Provided are a curable resin composition which includes oxide nanoparticles including indium and cerium, a monofunctional or higher functional (meth)acrylate compound, and a dispersant; a cured product formed of the curable resin composition; a diffractive optical element and a multilayer diffractive optical element; and oxide nanoparticles used in this composition.

Abstract: Additive manufacturing processes featuring consolidation of thermoplastic particulates may form printed objects in a range of shapes. Inorganic nanoparticles disposed upon the outer surface of the thermoplastic particulates may improve flow performance of the thermoplastic particulates during additive manufacturing, but may be undesirable to incorporate in some printed objects. Polymer nanoparticles may be substituted for inorganic nanoparticles in some instances to address this difficulty and provide other advantages. Particulate compositions suitable for additive manufacturing may comprise: a plurality of thermoplastic particulates comprising a thermoplastic polymer and a plurality of polymer nanoparticles disposed upon an outer surface of the thermoplastic particulates, the polymer nanoparticles comprising a crosslinked fluorinated polymer.

Abstract: A curable composition, a cured layer manufactured using the curable composition, a color filter including the cured layer, and a display device including the color filter, the curable composition including a quantum dot surface-modified with a first ligand and a second ligand having a structure different than the first ligand; and a polymerizable compound is provided. The first ligand is a silsesquioxane-based thiol ligand.

Abstract: Provided are a curable resin composition containing a compound represented by General Formula (1) and a component (B); and a cemented lens using the composition. Component (B): a polymer including a structural unit (bi) having an aromatic ring and a structural unit (b2) having a hydrogen bonding group, in which a proportion of the structural unit (b1) in all structural units constituting the polymer is 10% by mass or more and a proportion of the structural unit (b2) in all structural units constituting the polymer is 3% by mass or more, where the structural unit (bi) has no hydrogen bonding group. Pol1-Spa-L1-Ar-L2-Spb-Pol2??General Formula (1) Ar represents an aromatic ring group represented by a specific formula, L1, L2, Spa, and Spb represent a single bond or a specific group, and Pol1 and Pol2 represent a polymerizable group.